- Home
- OMCL
OMCL
Omnicell Inc. ($0.001 par value)
as 04-18-2025 1:41pm EST
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | FORT WORTH |
| Market Cap: | N/A | IPO Year: | 2001 |
| Target Price: | $50.67 | AVG Volume (30 days): | 644.4K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $25.12 - $55.75 | Next Earning Date: | 05-06-2025 |
| Revenue: | $1,112,238,000 | Revenue Growth: | -3.04% |
| Revenue Growth (this year): | 3.93% | Revenue Growth (next year): | 4.41% |
Stock Insider Trading Activity of Omnicell Inc. ($0.001 par value) (OMCL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LIPPS RANDALL A | OMCL | CHAIRMAN, PRESIDENT AND CEO | Mar 14 '25 | Buy | $33.13 | 10,561 | $349,874.31 | 333,610 |
Latest Omnicell Inc. ($0.001 par value) News
OMCL Breaking Stock News: Dive into OMCL Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Investors in Omnicell (NASDAQ:OMCL) have unfortunately lost 75% over the last three years
Argus Research
4 days ago
OMCL: Raising target price to $33.00
StockStory
4 days ago
Q4 Earnings Outperformers: Tandem Diabetes (NASDAQ:TNDM) And The Rest Of The Healthcare Technology Stocks
Business Wire
5 days ago
Omnicell to Release First Quarter 2025 Financial Results on May 6, 2025
StockStory
9 days ago
Omnicell, Royalty Pharma, EXL, IMAX, and OPENLANE Stocks Trade Down, What You Need To Know
Zacks
9 days ago
Here's Why Omnicell (OMCL) is a Strong Value Stock
Argus Research
11 days ago
OMCL: Lowering target price to $32.00
StockStory
11 days ago
Omnicell (OMCL): Buy, Sell, or Hold Post Q4 Earnings?
Compare OMCL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OMCL Omnicell Inc. ($0.001 par value) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.